



Neurotech
International

2026
Annual Report



Corporate Directory

Directors

Mark Davies
(Executive Chairman)

Anthony Filippis
(Managing Director and CEO)

Robert Maxwell Johnston
(Non-Executive Director)

Gerald Quigley
(Non-Executive Director and
Director of Public Relations)

Company Secretary

Alessandra Gauvin

Registered and Principal Office

Suite 102/Level 1, 55 Collins Street
Melbourne VIC 3000
03 9498 3132
www.neurotechinternational.com
info@neurotechinternational.com

Auditors

BDO Audit Pty Ltd
Level 9, Mia Yellagonga Tower 2
5 Spring Street
Perth WA 6000

Share Registry

Automatic Registry Services
Level 5, 191 St Georges Terrace
Perth WA 6000
08 9324 2099

Home Exchange

Australian Securities Exchange Ltd
Central Park
152-158 St Georges Terrace
Perth WA 6000

ABN: 73 610 205 402

ASX: NTI



Contents

Chairman's Letter	2
Directors' Report	6
Auditor's Independence Declaration	28
Financial Statements	30
Consolidated Statement of Profit or Loss and Other Comprehensive Income	31
Consolidated Statement of Financial Position	32
Consolidated Statement of Changes in Equity	33
Consolidated Statement of Cash Flows	34
Notes to the Consolidated Financial Statements	35
Consolidated Entity Disclosure Statement	56
Directors' Declaration	56
Independent Audit Report	57
Additional ASX Information	60

Chairman's Letter

Dear Shareholders, FY2026 was a defining year for Neurotech International Limited.

The Company moved from early-stage clinical development into developing a registration-enabling Phase III clinical trial in Autism Spectrum Disorder (ASD), a transition that represents an important evolution for Neurotech: no longer a company generating early clinical signals, but one building the evidence package intended to support the potential registration of NTI164.

That shift is the product of years of rigorous science, disciplined execution and a commitment to children living with serious neurological and neurodevelopmental disorders for whom treatment options remain limited or non-existent.

The year's most significant achievement was the initiation of Beyond Harmony, our Phase III trial evaluating NTI164 in children with ASD. Following Human Research Ethics Committee (HREC) approval, the first site was activated at Monash Children's Hospital, opening the study to enrolment and marking the point at which NTI164 entered the late stage of clinical development.

The opportunity before the Company is considerable. ASD affects millions of children globally, yet there remain few therapies that address the core symptoms of the condition.

NTI164 has already demonstrated statistically significant and clinically meaningful improvements across multiple symptom domains in earlier studies, providing the foundation for this registration-enabling clinical trial. Beyond Harmony has been designed to generate the clinical evidence intended to support regulatory submissions in both Australia and the United States, positioning Neurotech to pursue a significant unmet need in paediatric neurology.

Highlights FY2026

Phase III Underway

'Beyond Harmony' commenced at Monash Children's Hospital, advancing NTI164 into registration-enabling Phase III development for ASD.

Patient Access Expanded

Australian Authorised Prescriber Program launched, providing controlled access to NTI164 and generating valuable real-world clinical experience.

FDA Designation

Rare Paediatric Disease Designation granted to NTI164 for Rett Syndrome, complementing existing US Orphan Drug Designation.

Scientific Evidence Grows

Peer-reviewed Rett Syndrome and PANS studies published, strengthening the clinical and mechanistic evidence supporting NTI164.

Safety Package Strengthened

Positive 90-day GLP toxicology study supports the long-term dosing potential and regulatory development of NTI164.

Research Collaboration

University of Sydney collaboration commenced to further investigate NTI164's mechanism of action in Rett Syndrome.



Chairman's Letter

Directors' Report

Financial Statements

Additional Information

Importantly, this clinical study builds upon an increasingly comprehensive body of evidence supporting NTI164. During the year, the Company continued to strengthen the scientific and regulatory foundations of the program through peer-reviewed publications, positive long-term safety data, additional recognition from the US FDA, and the commencement of an Authorised Prescriber program that is providing eligible Australian patients with controlled access to treatment while generating valuable real-world clinical experience.

While ASD remains our highest priority, we also continued to explore NTI164's broader therapeutic potential through encouraging progress in Rett Syndrome and PANS, supporting our view that NTI164's reported anti-inflammatory and neuroprotective mechanisms may have application across multiple paediatric neurological disorders.

None of this progress would be possible without the dedication of our management team, clinical investigators, research partners, collaborators and, most importantly, the patients and families who place their trust in Neurotech by participating in our clinical studies. I also thank our shareholders for their continued support as we advance the Company towards this exciting next chapter.

As we look ahead, Neurotech enters the new financial year with clear priorities, a Phase III clinical program underway, and what we believe is an exceptional opportunity to create meaningful value for both patients and shareholders. We remain focused on executing our strategy and advancing NTI164 towards potential registration, with the goal of delivering a treatment that could make a lasting difference to children and families affected by neurological conditions around the world.

Yours sincerely,

Mark Davies
Executive Chairman
Neurotech International Limited



Chairman's Letter

Directors' Report

Financial Statements

Additional Information

Directors' Report



The Directors present their report together with the financial report of Neurotech International Limited and its controlled entities (Group) for the financial year ended 30 June 2026 and the Auditor's Report thereon.

Board of Directors

The names and details of the Directors in office during the financial period and until the date of this report are set out below.

Mark Davies	Executive Chairman*
Anthony Filippis	Managing Director & Chief Executive Officer
Gerald Quigley	Non-Executive Director
Robert Maxwell Johnston	Non-Executive Director

* Mark Davies held the role of Non-Executive Chairman during the full financial year ended 30 June 2026. He was appointed as Executive Chairman subsequent to the end of the financial year on 17 August 2026.

Principal Activities

Neurotech International Limited is a clinical-stage biopharmaceutical development company focused predominantly on paediatric neurological disorders with a broad-spectrum oral cannabinoid drug therapy called NTI164.

Neurotech has completed a Phase II/III randomised, double-blind, placebo-controlled clinical trial in Autism Spectrum Disorder (ASD) with clinically meaningful and statistically significant benefits reported across a number of clinically-validated measures and excellent safety.

In addition, Neurotech has completed and reported statistically significant and clinically meaningful Phase I/II trials in ASD and Paediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections (PANDAS) and Paediatric Acute-Onset Neuropsychiatric Syndrome (PANS), collectively PANDAS/PANS along with Rett Syndrome. Neurotech has received human ethics committee clearance for a Phase III Clinical Study in ASD.



Chairman's Letter

Directors' Report

Financial Statements

Additional Information

Dividends Paid or Recommended

The Directors of the Company do not recommend the payment of a dividend in respect of the current financial year ended 30 June 2026 (2025: Nil).

Operating Results

The consolidated Group's net loss after providing for income tax for the year ended 30 June 2026 amounted to \$6,538,516 (30 June 2025: \$10,598,859). Refer Note 1(c) on the preparation of the financial statements on a going concern basis.

Review of Operations

During FY2026, Neurotech advanced the clinical, regulatory and commercial development of NTI164, its proprietary broad-spectrum oral cannabinoid therapy, across a range of paediatric neurological disorders with significant unmet medical need.

The year was defined by the transition of the Company's flagship Autism Spectrum Disorder (ASD) program into a registration-enabling Phase III trial designed to support regulatory submissions. This was supported by four further milestones: the peer-reviewed publication of clinical data related to NTI164 in Rett Syndrome and PANS; the grant of Rare Paediatric Disease Designation by the US Food and Drug Administration (FDA) for NTI164 in Rett Syndrome; the completion of a key non-clinical safety study supporting long-term dosing; and the commencement of an Authorised Prescriber (AP) Program providing controlled patient access in Australia.

Autism Spectrum Disorder (ASD)

ASD remains Neurotech's flagship indication, with the year's key milestone being the advancement of NTI164 into a registration-enabling Phase III study designed to support regulatory submissions.

Neurotech initiated the first clinical site for its "Beyond Harmony" Phase III trial in March 2026, at Monash Children's Hospital, one of Australia's leading paediatric medical and research facilities, for patient screening and recruitment following receipt of all required regulatory approvals. Beyond Harmony is a multi-centre, randomised, double-blind, placebo-controlled study evaluating the efficacy, safety and tolerability of NTI164 in children diagnosed with ASD, with a focus on core symptoms and associated neuroinflammatory pathways. One hundred and fifty patients are planned for enrolment under an adaptive trial design, with change from baseline in the Vineland-3 Adaptive Behaviour Composite score as the primary endpoint, and Vineland-3 domain scores, SRS-2, CGI-I and CGI-S among the key secondary endpoints. Additional clinical sites are expected to be initiated as the study progresses.

Prior to this, HREC approval was received in February 2026 to commence the Beyond Harmony study in individuals with moderate-to-severe (Level II and III) ASD, a critical regulatory and strategic milestone that enabled the site activation and participant recruitment for the registration-enabling study. The study has been designed to generate the high-quality clinical data intended to support regulatory submissions for NTI164 in both Australia, through the Therapeutic Goods Administration (TGA), and the United States, through the FDA. Its design was informed by the statistically significant and clinically meaningful improvements demonstrated across multiple symptom domains, alongside consistent caregiver-reported, quality-of-life benefits, in the Company's prior ASD studies.

The program is led by Professor Michael Fahey as Principal Investigator, supported by a group of Co-Principal Investigators and a network of satellite clinical sites to be activated across Australia and progressively into the United States. The study is being conducted in accordance with ICH E6(R3) Good Clinical Practice (GCP), the ICH E8(R1) general considerations for clinical studies, and all applicable regulatory and ethical requirements of the TGA and FDA, with the objective of generating a clinical data package capable of supporting potential regulatory submissions for product registration in both jurisdictions.

Authorised Prescriber Program

In September 2025, Neurotech commenced an Authorised Prescriber (AP) Program for NTI164 in paediatric patients with a range of neurodevelopmental conditions in Australia. Managed by Professor Michael Fahey, the program provides an immediate, controlled and specialist-led pathway for eligible patients to access NTI164 in response to growing demand from patients and their families, while generating real-world clinical data to complement the Company's ongoing and planned registration trials.

The program has been structured to be broadly cost-neutral, with pricing set to cover the cost of supply plus a modest margin and is not positioned as a material revenue driver. It also establishes NTI164 within an evolving policy environment, including announced NDIS reforms under which children with mild ASD are expected to transition into a newly established program by mid-2027.

Rett Syndrome

The Company made important scientific and regulatory progress in its Rett Syndrome program during the year.

The Company's Phase I/II Rett Syndrome clinical trial results were published in July 2025 in the peer-reviewed *Journal of Paediatrics and Child Health*, titled "Full-Spectrum Medicinal Cannabis Plant Extract 0.08% THC (NTI164) Improves Symptoms of Rett Syndrome: An Open-Label Study". The publication reported that NTI164 was well tolerated and produced clinical improvements across key symptom areas relevant to Rett Syndrome, with potential broader therapeutic benefits across neurological, behavioural and functional measures. These findings provide further support for NTI164's proposed mechanism of action targeting neuroinflammation, glial dysregulation and synaptic function.

The strength of this clinical dataset was reflected in further regulatory recognition during the year. In October 2025, the US FDA granted Rare Pediatric Disease Designation (RPDD) to NTI164 for the treatment of Rett Syndrome, complementing the Orphan Drug Designation previously granted by the FDA. When pairing RPDD with Orphan Drug Designation, sponsors may also benefit from financial incentives including tax credits for clinical testing, exemption from certain FDA fees, and seven years of US market exclusivity if the therapy is approved.

Building on these results, Neurotech announced a research collaboration with The University of Sydney in February 2026 to further characterise the mechanism of action of NTI164 in Rett Syndrome. The program is being led by Professor Wendy Gold, Head of School of Medical Sciences (interim) in the Faculty of Medicine and Health, an internationally recognised expert in translating human neuronal modelling into mechanistic insight for neuro-developmental disorders. The research utilises human-derived Rett Syndrome neuronal models, enabling direct investigation of the disease-relevant cellular, molecular and functional abnormalities associated with MECP2 deficiency.





PANDAS/PANS

Neurotech announced the publication of clinical and mechanistic data for NTI164 in the peer-reviewed journal *Neurotherapeutics* in January 2026, the official journal of the American Society for Experimental NeuroTherapeutics and a high Impact Factor (6.9) publication.

The paper, titled “Medicinal cannabis plant extract (NTI164) modifies epigenetic, ribosomal, and immune pathways in paediatric acute-onset neuropsychiatric syndrome”, combined the clinical results from a sub-cohort of patients within the Company’s Phase I/II open-label PANS trial with a comprehensive multi-omics analysis of immune and epigenetic pathways.

The study evaluated NTI164 administered orally at 20 mg/kg/day over 12 weeks in 14 children with chronic, relapsing PANS. NTI164 was well tolerated, with no serious adverse events and only mild, self-limiting effects reported, and produced statistically significant improvements across all major disease domains, including:

- Overall disease severity (CGI-S improving from 4.8 to 3.3, $p=0.002$)
- Anxiety and emotional dysregulation (RCADS-P, $p<0.0001$)
- Obsessive-compulsive symptoms (CY-BOCS-II, $p=0.0001$)
- Tics (YGTSS, $p<0.0001$)
- ADHD symptoms (Conners, $p=0.028$)
- Quality of life (EQ-5D-Y, $p=0.011$)



Using integrated bulk and single-cell RNA sequencing, proteomics, phosphoproteomics and DNA methylation profiling, the investigators demonstrated that children with PANS exhibit widespread dysregulation of epigenetic, ribosomal and immune signalling pathways. Following NTI164 treatment, these pathways showed significant normalisation.

The publication consolidates clinical outcomes and mechanistic evidence previously reported to the market into a single peer-reviewed source, reinforcing the scientific foundation of Neurotech’s broader development program.

Non-Clinical Safety

In February 2026, Neurotech announced positive results from a 90-day repeat-dose oral toxicity study of NTI164 in a non-rodent species (Beagle dogs), a key component of the Company’s safety package to the FDA and TGA. The study was conducted in accordance with US FDA Good Laboratory Practice (GLP) requirements and demonstrated a favourable safety and tolerability profile across all dose levels, with no mortality and no dose-limiting toxicities observed. NTI164 was well tolerated at the highest administered dose of 216 mg/kg/day, dosed twice daily over the 90-day period, representing approximately ten times the highest prescribed human dose evaluated to date in prior completed studies.

There were no clinically meaningful adverse effects on body weight, food consumption, haematology, coagulation parameters or general clinical observations throughout the dosing phase. Any treatment-related findings at higher dose levels were mild and reversible, with full recovery observed following a 14-day non-dosing period, and no progressive, irreversible or life-threatening toxicities were identified. Following consultation with the US FDA through Type C and Type D meeting interactions, additional central nervous system-focused safety assessments, including enhanced brain sectioning and detailed analysis, were incorporated into the study and did not identify any neurological safety concerns.

The results support the long-term dosing potential of NTI164 and strengthen the Company’s safety package for future regulatory interactions.

Regulatory Strategy

Neurotech continued to pursue a dual regulatory pathway spanning Australia, through the TGA, and the United States, through the FDA. The “Beyond Harmony” Phase III study has been designed to support potential product registration submissions in both jurisdictions.

The Company further strengthened its regulatory position during the year through the granting of FDA Rare Pediatric Disease Designation for NTI164 in Rett Syndrome, complementing the existing Orphan Drug Designation in this indication; the completion of its GLP non-rodent toxicology study; and continued formal engagement with the FDA, including Type C and Type D meeting interactions, in preparation for Neurotech’s Investigational New Drug (IND) submissions.



Mente Device

Neurotech has previously noted its intention to divest of the operations of its wholly owned subsidiaries, AAT Medical Ltd and AAT Research Ltd ('Subsidiaries'), being the Subsidiaries managing the Company's neurofeedback device, Mente.

As set out in the quarterly activities report for the period ended 30 June 2025, the Company announced that it has made the decision, and taken steps, to place these Subsidiaries into voluntary liquidation. The decision to do so was difficult but necessary given the very small number of children using the device to date and no material sales over the period. The Company will focus all its resources and capital on the clinical and commercial development of NTI164.

Key Risks

The Company is exposed to risks typical of a clinical-stage biopharmaceutical business, including uncertainty around clinical trial outcomes, regulatory approvals, intellectual property protection, product manufacturing and commercialisation. The Company is substantially dependent on the successful development of NTI164.

Drug development is inherently uncertain. Preclinical or early-stage clinical results may not be replicated in larger or later-stage trials, clinical trials may be delayed or affected by difficulties in patient recruitment and retention, and adverse safety findings may arise. Regulatory authorities may require additional studies, data or manufacturing validation, and there can be no assurance that regulatory approvals will be obtained or maintained, or that an approved product will achieve reimbursement, clinician acceptance or commercial success.

The Company relies on third-party manufacturers, clinical sites, laboratories, advisers and suppliers. While manufacturing risk is mitigated through production across three Australian facilities, supply disruption, quality issues or contractor non-performance may still affect timelines and costs.

The Company also faces funding, competition, key personnel, cybersecurity, foreign-exchange and cannabinoid regulatory risks. It seeks to manage these risks through specialist advisers, experienced clinicians, quality controls and established contractor and supplier relationships.



Corporate Activity

Neurotech undertook an active program of investor engagement through the year to raise awareness of the Company and NTI164, including presentations by Managing Director and CEO Dr Anthony Filippis at the Ignite Investment Summit in Hong Kong in April 2026, Gold Coast Investment Showcase in June 2026, Australian Microcap Investment Conference in May 2026 and the NWR Virtual Healthcare Conference in March 2026. In May 2026, the Company also hosted an advocacy day, bringing together families, healthcare professionals, shareholders and other interested parties to hear about the Company's work and the real-world impact of NTI164. Alongside these activities, the Company progressed an outreach program to socialise and nurture potential future partnering opportunities for NTI164.

In December 2025, the Company initiated a placement and subsequently received approximately \$3,753,676 in total, through the issue of new fully paid ordinary shares at an issue price of \$0.014 per share (across two tranches).

Support was received from existing and new institutional, professional and sophisticated investors, and all directors elected to participate for a total of approximately \$250,000, subject to shareholder approval, which was received at a General Meeting held in March 2026. Funds raised have been applied towards advancing NTI164 non-clinical toxicology and registration-enabling clinical programs, progressing regulatory submissions, and supporting general working capital.

Earlier in the year, the Company received a research and development (R&D) tax incentive refund of \$4,734,327 for the financial year ended 30 June 2025, under the Australian Government's R&D tax incentive scheme, which provided eligible companies with a refundable tax offset of up to 48.5%. The refund provided an important source of non-dilutive funding to support the Company's clinical development pipeline and working capital.



Matters Subsequent to the End of the Financial Year

US FDA Clears IND for NTI164

In July 2026, the Company announced that the US Food and Drug Administration (FDA) has cleared the Company's Investigational New Drug (IND) submission for NTI164.

The IND clearance authorises Neurotech to commence its proposed clinical development program for NTI164 in the United States and represents a major regulatory milestone for the Company. The IND submission included the Company's chemistry, manufacturing and controls (CMC), non-clinical and clinical information supporting the proposed clinical and development program.

Should the Company elect to commence clinical development in the United States, the study to be conducted under the FDA-cleared IND will be a comprehensive population pharmacokinetic (PopPK) program. The program has been strategically designed to complement the Company's Australian Phase III "Beyond Harmony" trial, which is intended to generate pivotal efficacy and safety data for NTI164 in paediatric patients with ASD. The Phase III results are expected to form an important component of the global clinical evidence package supporting future regulatory submissions, while the US PopPK study would generate vital pharmacokinetic data to support characterisation and product registration initiatives.

Notices of Allowance for Two US Patent Applications

In July 2026, the Company advised that the United States Patent and Trademark Office (USPTO) sent Notices of Allowance for US patent applications No. 18/698,605 and No. 19/335,945 to Neurotech. These applications relate to key aspects of the Company's NTI164 product and are both titled "Compositions and Methods for Treating Neurological Disorders".

The allowed claims of US Patent Application No. 18/698,605 cover methods of reducing neuroinflammation using NTI164 and the allowed claims of US Patent Application No. 19/335,945 are specifically directed to methods of treating autism spectrum disorder.

Once granted, these patents are expected to further strengthen Neurotech's intellectual property portfolio for NTI164, which is currently in Phase III clinical development for the treatment of ASD in paediatric patients. The patents will not be enforceable until formally granted. The Notices of Allowance confirm that the USPTO has determined the applications meet the requirements for patentability and issuance of two US patents is expected within the coming months, subject to completion of standard administrative processes. Subject to the payment of applicable maintenance fees, these patents are expected to provide intellectual property protection for NTI164 through to 2042.

\$3,150,000 R&D Tax Incentive Loan

In July 2026, Neurotech entered into a secured loan agreement and specific security agreement with Rockford RDF Pty Ltd as trustee for the Rockford RDF Unit Trust for a secured loan of \$3,150,000.

The loan provides Neurotech with non-dilutive funding secured against the Company's anticipated refundable research and development tax incentive offsets for FY2026 and FY2027. Further details on this loan are set out in the Company's ASX announcement dated 15 July 2026.

Receipt of Binding Commitments for ~\$4,500,000 Placement

In August 2026, Neurotech announced the receipt of binding commitments from investors totalling approximately \$4,500,000 (before costs) through the placement of new fully paid ordinary shares in two tranches ('Placement Shares') at an issue price of \$0.014 per share ('Placement'). The Placement was supported by existing and new institutional and sophisticated investors and was managed by Taylor Collison Limited and Canary Capital Pty Ltd as Joint Lead Managers.

Funds raised will predominantly be used to fund the Company's Phase III double-blind, placebo-controlled clinical trial of NTI164 in children with Autism Spectrum Disorder (ASD), as well as regulatory activities, general working capital and costs associated with the Placement. Subject to completion of the Placement, based on Neurotech's current clinical development plan and budget, and together with its existing cash, the Company expects that the net proceeds of the Placement will fund Neurotech through to topline data readout from the Phase III clinical trial which is anticipated to represent a significant milestone in the Company's development pathway for NTI164.

Appointment of Executive Chairman

In August 2026, the Company announced the appointment of Mr Mark Davies as Executive Chairman of the Company, effective 17 August 2026. Mr Davies transitioned from his previous role as Non-Executive Chairman.

As Executive Chairman, Mr Davies will assume a more active role in the strategic and operational leadership of Neurotech. His responsibilities will include corporate strategy, capital markets and funding initiatives, partnering and licensing activities, investor engagement, governance, and strategic oversight of the Company's clinical and regulatory programs.

The appointment reflects the Company's progression into its next stage of development, with an increased focus on the Phase III program, funding and potential partnering and licensing opportunities.

Significant Changes in State of Affairs

Other than detailed in the Review of Operations, there were no significant changes in the state of affairs of the Group during the financial year.

AGM

The Company anticipates that it will hold its next Annual General Meeting ('AGM') on or after 4 November 2026.

In accordance with ASX Listing Rule 3.13.1, the closing date for the receipt of nominations from persons wishing to be considered for election as a director of the Company is 16 September 2026.

Any nominations must be received in writing no later than 5.00pm (AEST) on 16 September 2026 at the Company's registered office.

Environmental Regulation

The Entity's operations are not subject to any particular and significant environmental regulation under a law of the Commonwealth or of a State or Territory, including the reporting requirements of the *National Greenhouse and Energy Reporting Act 2007 (Cth)*.



Board of Directors

Mark Davies - Executive Chairman

Experience and Expertise

Mark Davies graduated from the University of Western Australia with a Bachelor of Commerce. He has over 20 years' experience in trading, investment banking and providing corporate advice. He worked at Montagu Stockbrokers before co-founding investment banking firm Cygnet Capital and more recently 1861 Capital. Mark specialises in providing corporate advice and capital raising services to emerging companies seeking business development opportunities and funding from the Australian market.

Other Current Directorships	None
Former Directorships in Last 3 Years	Non-Executive Chairman of Tryptamine Therapeutics Limited (ASX: TYP)
Special Responsibilities	Non-Executive Chairman (15 August 2022 to 16 August 2026) Executive Chairman (appointed 17 August 2026)
Interests in Shares and Options	18,935,875 ordinary shares

Anthony Filippis - Managing Director and CEO

Experience and Expertise

Dr Anthony Filippis is a seasoned executive with over 25 years of leadership experience across the biotechnology, healthcare, and investment sectors. His expertise spans multiple therapeutic areas, including neuroscience, oncology, and endocrinology, with a particular focus on commercialising innovative clinical therapeutics for diseases with high unmet medical need.

Over the course of his career, Anthony has held senior roles at several ASX-listed and private life sciences companies. He has a proven track record in driving strategic partnerships, securing capital to advance clinical programs, and leading negotiations for in- and out-licensing agreements, as well as mergers and acquisitions.

In addition to his PhD in Biochemistry, Anthony holds an MBA and actively contributes to the industry through his roles on various boards and committees, as well as mentoring emerging leaders.

Other Current Directorships	Non-Executive Director of VivaZome Therapeutics Pty Ltd Non-Executive Director of Connectivity Limited
Former Directorships in Last 3 Years	None
Special Responsibilities	Executive Management, Strategy
Interests in Shares and Options	3,571,428 ordinary shares 10,000,000 unlisted options (\$0.16, 24 February 2030) 10,000,000 unlisted options (\$0.18, 24 February 2030)

Robert Maxwell Johnston - Non-Executive Director

Experience and Expertise

Prior to his non-executive director career, Mr Johnston held the position of President and Chief Executive Officer of Johnson and Johnson Pacific, a division of the world's largest healthcare company for 11 years.

Prior to this appointment, his career included several positions within Johnson and Johnson, both within Australia and overseas encompassing Europe and Asia. Mr Johnston's career also included senior roles within Australia and overseas with Unilever and Guinness-United Distillers and several prominent industry body roles as past President of ACCORD Australasia Limited, Vice Chairman of AFGC, and Board Member of ASMI.

Other Current Directorships	Non-Executive Director of Inoviq Ltd (ASX: IIQ)
Former Directorships in Last 3 Years	None
Interests in Shares and Options	4,604,761 ordinary shares

Gerald Quigley - Non-Executive Director and Director of Public Relations

Experience and Expertise

Mr Quigley is a pharmacist and consumer health commentator. As a leading media health commentator, he is heard each week on television and radio stations across Australia.

He has extensive knowledge relating to pharmaceutical and nutraceutical product development, dispensing and marketing in addition to product positioning within the relevant regulatory landscapes (e.g. TGA, FDA). Mr Quigley holds a Bachelor of Pharmacy.

Other Current Directorships	None
Former Directorships in Last 3 Years	None
Special Responsibilities	Public Relations (appointed 7 July 2022)
Interests in Shares and Options	3,849,205 ordinary shares

Company Secretary

Alessandra Gauvin - Company Secretary

Experience and Expertise

Mrs Gauvin is an experienced corporate governance professional with over eight years of company secretarial experience working with ASX-listed companies across a diverse range of industries including mining, technology, biotech and industrials.

Mrs Gauvin is a Chartered Secretary. She holds a Bachelor of Commerce (Accounting and Business Law) and a Graduate Diploma in Applied Corporate Governance from the Governance Institute of Australia.



Board Meetings Attendance

Attendances by each Director during the year were as follows:

Director	Number Eligible to Attend	Number Attended
Mark Davies	6	6
Anthony Filippis	6	6
Gerald Quigley	6	6
Robert Maxwell Johnston	6	6

Remuneration Report (Audited)

This Remuneration Report outlines the Director and Executive remuneration arrangements of the Group and has been audited in accordance with the requirements of section 308(3C) of the *Corporations Act 2001* and the Corporations Regulations 2001.

For the purposes of this report, Key Management Personnel of the Group are defined as those persons having authority and responsibility for planning, directing and controlling the major activities of the Group and the Consolidated Entity, directly or indirectly, including any Director (whether Executive or otherwise) of the Group.

Key Management Personnel Disclosed in the Report

The names and positions held of Parent Entity Directors and Key Management Personnel in office at any time during the financial year are:

Director	
Mark Davies	Non-Executive Chairman (subsequently appointed Executive Chairman on 17 August 2026)
Anthony Filippis	Managing Director & Chief Executive Officer
Robert Maxwell Johnston	Non-Executive Director
Gerald Quigley	Non-Executive Director

Remuneration Governance

The full Board filling the role of the Nomination and Remuneration Committee is responsible with respect to the following:

- (a) remuneration policies and practices;
- (b) remuneration of the Executive Officer and Executive Directors;
- (c) composition of the Board; and
- (d) performance management of the Board and of the Chief Executive Officer.

Use of Remuneration Consultants

During the year, the Group has not required or used any remuneration consultants.

Executive Remuneration Policy and Framework

The full Board reviews and makes recommendations regarding the following:

- (a) service contracts in place between KMP and Company;
- (b) strategies in relation to Executive remuneration policies;
- (c) compensation arrangements for the Chairman, Non-Executive Directors, CEO, and other Senior Executives as appropriate;
- (d) performance related incentive policies;
- (e) the Group's recruitment, retention and termination policies;
- (f) the composition of the Board having regard to the skills/experience desired and skills/experience represented;
- (g) the appointment of Board members;
- (h) the evaluation of the performance of the CEO;
- (i) consideration of potential candidates to act as Directors; and
- (j) succession planning for Board members.

Key Management Personnel Remuneration Policy

The Board's policy for determining the nature and amount of remuneration of Key Management Personnel for the economic entity is as follows:

The remuneration structure for Key Management Personnel is based on a number of factors including particularly the skills and experience of the individual concerned. The contracts for service between the Group and Key Management Personnel are on a continuing basis, subject to review with the Board proposing a review in the immediate future. There is no scheme to provide retirement benefits, other than statutory superannuation.

Upon their respective appointment to the Company, all Directors and executives enter into an agreement with the Group.

The structure of the performance-based elements of an Executive's remuneration is designed to encourage retention of the Executives while also rewarding short-term performance of the individual and long-term performance of the Group, and therefore contributing to the wealth of the Group's shareholders. Executives are subject to an annual performance review against objectives relevant to their role, and the performance against these objectives is used to determine the amount of their annual short-term incentive bonus received.



Key Management Personnel Compensation

The compensation of the Group's Key Management Personnel is disclosed below:

2026 Key Management Person	Short-Term Benefits				Termination Benefits	Share-Based Payment			Total (\$)	Performance Related
	Salary (\$)	Other (\$)	Post Retirement Benefits (\$)	Annual Leave (\$)	Termination Benefits (\$)	Shares (\$)	Options (\$)	Total Share-Based Payments (\$)		
Directors										
Mark Davies	100,000	-	-	-	-	-	-	-	100,000	-
Robert Maxwell Johnston	50,000	-	-	-	-	-	-	-	50,000	-
Gerald Quigley	50,000	-	-	-	-	-	-	-	50,000	-
Anthony Filippis ¹	420,000	-	50,400	14,016	-	-	128,883	128,883	613,299	21%
Total	620,000	-	50,400	14,016	-	-	128,883	128,883	813,299	

Remuneration and other terms of employment for key management personnel are formalised in service agreements. Details of these agreements are as follows:

Name	Title	Agreement Commenced	Term of Agreement	Notice Period	Annual Remuneration	Termination Benefits
Mark Davies	Non-Executive Chairman (subsequently appointed Executive Chairman on 17 August 2026)	27 May 2019	No fixed term	-	\$100,000 plus GST	-
Gerald Quigley	Non-Executive Director	7 July 2022	No fixed term	-	\$50,000	-
Robert Maxwell Johnston	Non-Executive Director	19 April 2024	No fixed term	-	\$50,000 plus GST	-
Anthony Filippis	Managing Director, CEO	1 February 2025	No fixed term	4 months	\$468,300 inclusive of superannuation	-

¹ Upon agreement to appoint Dr Filippis as Managing Director and CEO, the Company issued the following options to Dr Filippis' nominee. The options were issued on 24 February 2025 and valued using an Up and In Trinomial model with the following input:

	NTIOPT28		NTIOPT29	
	Tranche 1	Tranche 2	Tranche 3	Tranche 4
Number of options in series	5,000,000	5,000,000	5,000,000	5,000,000
Issue date share price	\$0.05	\$0.05	\$0.05	\$0.05
Exercise price	\$0.16	\$0.16	\$0.18	\$0.18
Expected volatility	68%	68%	68%	68%
Option life	5 years	5 years	5 years	5 years
Expiry	24/02/2030	24/02/2030	24/02/2030	24/02/2030
Interest rate	4.183%	4.183%	4.183%	4.183%
Valuation per option	\$0.013	\$0.017	\$0.007	\$0.006
Valuation per tranche	\$66,911	\$85,179	\$35,000	\$30,000
Expensed in the period	\$39,597	\$56,786	\$17,500	\$15,000

The above options hold the following vesting conditions:

- 5,000,000 Tranche 1 NTIOPT28 options will vest on the first anniversary of the commencement date of Dr Anthony Filippis as Managing Director and CEO, which happened on 1 February 2025 ('Commencement Date').
- 5,000,000 Tranche 2 NTIOPT28 options will vest upon an 18-month period of continuous service in the position from the Commencement Date and the Company filing a market registration application (which is approved by the Board) for NTI164 with the appropriate health regulator in any one of the following markets: Australia, United States of America, European Union, United Kingdom or the Republic of Korea.
- 5,000,000 Tranche 3 NTIOPT29 options will vest upon a 24-month period of continuous service in the position, commencing upon the Commencement Date and Neurotech enters into and completes a legally binding licensing transaction and the Company achieving, after the Commencement Date, an Undiluted Market Capitalisation of at least \$200 million for at least 10 consecutive trading days.
- 5,000,000 Tranche 4 NTIOPT29 options will vest upon a 24-month period of continuous service and the Company announcing to the ASX the receipt by the Company of proceeds from the Company's first commercial sale of NTI164 in any market following regulatory approval by the appropriate health regulator (but not including the sale of NTI164 through any special access scheme or authorised prescriber pathway in Australia or in any other market) and the Company achieving, after the Commencement Date, an Undiluted Market Capitalisation of at least \$300 million for at least 10 consecutive trading days.



2025 Key Management Person	Short-Term Benefits				Termination Benefits	Share-Based Payment			Total (\$)	Performance Related
	Salary (\$)	Other (\$)	Post Retirement Benefits (\$)	Annual Leave (\$)	Termination Benefits (\$)	Shares (\$)	Options (\$)	Total Share-Based Payments (\$)		
Directors										
Mark Davies	100,000	-	-	-	-	-	-	-	100,000	-
Robert Maxwell Johnston	50,000	-	-	-	-	-	(12,427)	(12,427)	37,573	-33%
Gerald Quigley	50,000	-	-	-	-	-	-	-	50,000	-
Thomas Duthy ¹	195,000	-	-	-	-	-	27,018	27,018	222,018	12%
Anthony Filippis	175,000	-	20,125	6,462	-	-	63,764	63,764	265,351	24%
Management										
Dr Alexandra Andrews ²	4,654	-	6,496	9,429	60,000	-	-	-	80,579	-
Total	574,654	-	26,621	15,891	60,000	-	78,355	78,355	755,521	

¹ Resigned 1 April 2025
² Ceased employment 26 July 2024

Equity Instruments Disclosure Relating to Key Management Personnel

Shares

Number of shares held by Parent Entity Directors and other Key Management Personnel of the Group, including their personally related parties, are set out below.

Name	Balance at the Start of the Year	Acquired as Part of Remuneration	Placement	Exercise of Options	Disposed	Other	Balance at the End of the Year
Directors							
Mark Davies	11,793,017	-	7,142,858	-	-	-	18,935,875
Robert Maxwell Johnston	1,033,333	-	3,571,428	-	-	-	4,604,761
Gerald Quigley	277,777	-	3,571,428	-	-	-	3,849,205
Anthony Filippis	-	-	3,571,428	-	-	-	3,571,428
Total	13,104,127	-	17,857,142	-	-	-	30,961,269

Options

Number of options held by Parent Entity Directors and other Key Management Personnel of the Group, including their personally related parties, are set out below.

Name	Balance at the Start of the Year	Acquired as Part of Remuneration	Exercised	Other*	Balance at the End of the Year	Vested and Exercisable
Directors						
Mark Davies	-	-	-	-	-	-
Gerald Quigley	5,000,000	-	-	(5,000,000)	-	-
Robert Maxwell Johnston	1,000,000	-	-	(1,000,000)	-	-
Anthony Filippis	20,000,000	-	-	-	20,000,000	5,000,000
Total	26,000,000	-	-	(6,000,000)	20,000,000	5,000,000

* Lapse of options

Voting and Comments Made at the Group’s 2025 Annual General Meeting

The Group received a 95.49% “yes” vote on its remuneration report for the 2025 financial year (2024: 97.37% yes). The Group did not receive any specific feedback at the AGM or throughout the year on its remuneration practices.

Transactions with Related Parties

During the reporting period, there were no related party transactions between related parties and Neurotech International Limited.

This is the end of the Audited Remuneration Report.





Indemnification of Directors and Officers

(a) Indemnification

The Group has agreed to indemnify the current Directors and Group Secretary of the Group against all liabilities to another person (other than the Group or a related body corporate) that may arise from their position as Directors and Group Secretary of the Group, except where the liability arises out of conduct involving a lack of good faith.

The Agreement stipulates that the Group will meet to the maximum extent permitted by law, the full amount of any such liabilities, including costs and expenses.

(b) Insurance Premiums

During the year ended 30 June 2026, the Company paid insurance premiums in respect of Directors and Officers Liability Insurance for Directors and Officers of the Company. The liabilities insured are for damages and legal costs that may be incurred in defending civil or criminal proceedings that may be brought against the Directors and Officers in their capacity as Directors and Officers of the Company to the extent permitted by the *Corporations Act 2001*. The contract of insurance prohibits disclosure of the nature of the liability and the amount of the premium.

Non-Audit Services

No non-audit services were provided by the Group's auditor during the year ended 30 June 2026 or 30 June 2025.

Indemnity and Insurance of Auditor

The Group has not, during or since the end of the financial year, indemnified or agreed to indemnify the auditor of the Group or any related entity against a liability incurred by the auditor. During the financial year, the Group has not paid a premium in respect of a contract to insure the auditor of the Group or any related entity.

Corporate Governance

The Board is responsible for the overall corporate governance of the Group, and it recognises the need for the highest standards of ethical behaviour and accountability. It is committed to administering its corporate governance structures to promote integrity and responsible decision making.

The Group's corporate governance structures, policies and procedures are described in its Corporate Governance Statement which is available at the Group's website at: <http://neurotechinternational.com/investor-centre/corporate-governance>

Shares

As at the date of this report there are 1,616,069,964 (2025: 1,049,621,921) ordinary shares on issue.

Options

All options granted confer a right of one ordinary share for every option held.

The Group has the following unlisted options on issue as at 30 June 2026:

Grant Date	Expiry Date	Exercise Price (\$)	Balance at End of the Year Number	Vested and Exercisable Number
23/12/2022	23/12/2027	\$0.10	10,000,000	10,000,000
23/12/2022	23/12/2027	\$0.15	10,000,000	10,000,000
08/11/2024	24/02/2030	\$0.16	10,000,000	5,000,000
08/11/2024	24/02/2030	\$0.18	10,000,000	-
			40,000,000	25,000,000

Performance Rights

The Group has the following performance rights on issue as at 30 June 2026:

Class	Grant Date	Expiry Date	Number of Rights
Class C	31/05/2024	31/05/2027	5,000,000
Class D	31/05/2024	31/05/2027	10,000,000
Class E	31/05/2024	31/05/2027	20,000,000
			35,000,000

Rounding Off

The Company is an entity to which ASIC Corporations (Rounding in Financial/ Directors' Reports) Instrument 2026/183, issued by the Australian Securities and Investments Commission, applies. Amounts in the Financial Statements have been rounded to the nearest dollar, unless otherwise stated.



Auditor's Independence Declaration

The Auditor's Independence Declaration as required under section 307C of the *Corporations Act 2001* for the year ended 30 June 2026 has been received and can be found on page 29.

This report is made in accordance with a resolution of Directors, pursuant to section 298(2)(a) of the *Corporations Act 2001*.

Signed on behalf of the Board of Directors.

Mark Davies
Executive Chairman
26 August 2026



Tel: +61 8 6382 4600
Fax: +61 8 6382 4601
www.bdo.com.au

Level 9, Mia Yellagonga Tower 2
5 Spring Street
Perth, WA 6000
PO Box 700 West Perth WA 6872
Australia

DECLARATION OF INDEPENDENCE BY JOHN CHRISTIDES TO THE DIRECTORS OF NEUROTECH INTERNATIONAL LIMITED

As lead auditor of Neurotech International Limited for the year ended 30 June 2026, I declare that, to the best of my knowledge and belief, there have been:

1. No contraventions of the auditor independence requirements of the *Corporations Act 2001* in relation to the audit; and
2. No contraventions of any applicable code of professional conduct in relation to the audit.

This declaration is in respect of Neurotech International Limited and the entities it controlled during the period.

John Christides
Director

BDO Audit Pty Ltd
Perth
26 August 2026

BDO Audit Pty Ltd ABN 33 134 022 870 is a member of a national association of independent entities which are all members of BDO International Ltd, a UK company limited by guarantee, and form part of the international BDO network of independent member firms. Liability limited by a scheme approved under Professional Standards Legislation.

Financial Statements

Consolidated Statement of Profit or Loss and Other Comprehensive Income

For the Year Ended 30 June 2026

	Notes	Consolidated	
		30 June 2026 (\$)	30 June 2025 (\$)
Continuing Operations			
Revenue		-	238
Other income	3	4,807,234	2,581,232
Professional consultant and advisory expenses		(372,143)	(441,472)
Professional legal expenses		(43,800)	(103,032)
Corporate and administration expenses		(576,098)	(666,972)
Depreciation and amortisation expenses		-	(289)
Advertising and marketing expenses		(2,631)	(4,645)
Employee benefits expense		(677,954)	(794,553)
Share-based payments expense	4	(612,216)	(1,580,044)
Research expense	5	(9,047,315)	(9,941,888)
Other expenses		(13,593)	352,566
Loss Before Income Tax		(6,538,516)	(10,598,859)
Income tax benefit	6	-	-
Loss After Income Tax		(6,538,516)	(10,598,859)
Other comprehensive income/(loss)		-	-
Items that may be reclassified subsequently to profit or loss:			
Exchange difference on translation of foreign operations		3,230	(354,849)
Total Comprehensive Loss for the Year		(6,535,286)	(10,953,708)
Basic Loss Per Share (Cents Per Share)	21	(0.55)	(1.02)
Diluted Loss Per Share	21	(0.55)	(1.02)

The Consolidated Statement of Profit or Loss and Other Comprehensive Income is to be read in conjunction with the accompanying notes.

Consolidated Statement of Financial Position

As at 30 June 2026

	Notes	Consolidated	
		30 June 2026 (\$)	30 June 2025 (\$)
Current Assets			
Cash and cash equivalents	9	2,386,402	3,030,955
Trade and other receivables	10	342,338	88,704
Prepayments		18,652	120,632
Total Current Assets		2,747,392	3,240,291
Total Assets		2,747,392	3,240,291
Current Liabilities			
Trade and other payables	11	2,122,235	279,280
Provisions	12	14,016	6,462
Total Current Liabilities		2,136,251	285,742
Total Liabilities		2,136,251	285,742
Net Assets		611,141	2,954,549
Equity			
Contributed equity	13	52,494,008	48,914,346
Reserves	14	6,811,803	6,196,357
Accumulated losses	15	(58,694,670)	(52,156,154)
Total Equity		611,141	2,954,549

The Consolidated Statement of Financial Position is to be read in conjunction with the accompanying notes.

Consolidated Statement of Changes in Equity

For the Year Ended 30 June 2026

	Contributed Equity (\$)	Accumulated Losses (\$)	Share-Based Payment Reserve (\$)	Foreign Currency Translation Reserve (\$)	Total (\$)
Financial Year Ended 30 June 2026					
Balance at 1 July 2025	48,914,346	(52,156,154)	6,856,545	(660,188)	2,954,549
(Loss) for the year	-	(6,538,516)	-	-	(6,538,516)
Exchange difference	-	-	-	3,230	3,230
Total Comprehensive (Loss)	-	(6,538,516)	-	3,230	(6,535,286)
Transactions with equity holders in their capacity as equity holders					
Placement shares	3,753,677	-	-	-	3,753,677
Share-based payments (Note 4)	-	-	612,216	-	612,216
Share issue cost	(174,015)	-	-	-	(174,015)
Balance at 30 June 2026	52,494,008	(58,694,670)	7,468,761	(656,958)	611,141

Consolidated Statement of Changes in Equity

For the Year Ended 30 June 2025

	Contributed Equity (\$)	Accumulated Losses (\$)	Share-Based Payment Reserve (\$)	Foreign Currency Translation Reserve (\$)	Total (\$)
Financial Year Ended 30 June 2025					
Balance at 1 July 2024	46,734,820	(41,557,295)	7,026,501	(305,339)	11,898,687
(Loss) for the year	-	(10,598,859)	-	-	(10,598,859)
Exchange difference	-	-	-	(354,849)	(354,849)
Total Comprehensive (Loss)	-	(10,598,859)	-	(354,849)	(10,953,708)
Transactions with equity holders in their capacity as equity holders					
Share issues on conversion of options (Note 13)	434,000	-	-	-	434,000
Conversion of performance right	1,050,000	-	(1,050,000)	-	-
Share-based payments (Note 4)	-	-	1,580,044	-	1,580,044
Share issue to Fenix	700,000	-	(700,000)	-	-
Share issue cost	(4,474)	-	-	-	(4,474)
Balance at 30 June 2025	48,914,346	(52,156,154)	6,856,545	(660,188)	2,954,549

The Consolidated Statement of Changes in Equity is to be read in conjunction with the accompanying notes.

Consolidated Statement of Cash Flows

For the Year Ended 30 June 2026

	Notes	Consolidated	
		30 June 2026 (\$)	30 June 2025 (\$)
Cash Flows From Operating Activities			
Receipts from customers		-	238
R&D tax refund		4,734,328	2,444,143
Payments to suppliers and employees		(9,003,183)	(11,605,521)
Interest received		44,640	137,089
Net Cash Used in Operating Activities	16	(4,224,215)	(9,024,051)
Cash Flows From Investing Activities			
Net Cash Used in Investing Activities		-	-
Cash Flows From Financing Activities			
Proceeds from issue of shares, net of costs		3,579,662	429,526
Net Cash Provided by Financing Activities		3,579,662	429,526
Net (Decrease) in Cash Held		(644,553)	(8,594,525)
Cash and cash equivalents at beginning of financial year		3,030,955	11,625,480
Cash and Cash Equivalents at End of Financial Year	9	2,386,402	3,030,955

The Consolidated Statement of Cash Flows is to be read in conjunction with the accompanying notes.

Notes to the Consolidated Financial Statements

1. Statement of Material Accounting Policies

The material accounting policies adopted in the preparation of the Financial Statements are set out below. These policies have been consistently applied to all years presented, unless otherwise stated.

(a) General Information

Neurotech International Limited (Company) or (Entity) is a public company limited by shares, incorporated in Australia with operations in Malta. The Consolidated Financial Report of the Company as at and for the year ended 30 June 2026 comprises the Company and its subsidiaries (together referred to as the ‘Consolidated Entity’ or ‘Group’).

Neurotech International Limited is a biotechnology company conducting clinical studies to assess the neuro-protective, anti-inflammatory and neuro-modulatory activities of its proprietary cannabis strains.

The nature of the operations and principal activities of the Consolidated Entity are described in the Directors’ Report.

(b) Basis of Preparation

The financial report is a general-purpose financial report which has been prepared in accordance with Australian Accounting Standards and Interpretations issued by the Australian Accounting Standards Board and the *Corporations Act 2001*. Neurotech International Limited is a for-profit entity for the purpose of preparing the Financial Statements.

Australian Accounting Standards set out accounting policies that the AASB has concluded would result in a financial report containing relevant and reliable information about transactions, events and conditions. Compliance with Australian Accounting Standards ensures that the financial statements and notes also comply with International Financial Reporting Standards as issued by the IASB. Material accounting policies adopted in the preparation of this financial report are presented below and have been consistently applied.

The Financial Statements were approved by the Board of Directors on 26 August 2026.

(i) Comparatives

When required by Accounting Standards, comparative figures have been adjusted to conform to changes in presentation for the current financial year.

(c) Going Concern

The Directors are satisfied that the going concern assumption has been appropriately applied in preparing the financial statements and the historical financial information has been prepared on a going concern basis, which contemplates the continuity of normal business activity and the realisation of assets and the settlement of liabilities in the normal course of business.

For the year ended 30 June 2026 the Group made an operating loss of \$6,538,516 (2025: loss of \$10,598,859), had cash outflows from operating activities of \$4,224,215 (2025: \$9,024,051). The Company had cash on hand as at 30 June 2026 of \$2,386,402 (2025: \$3,030,955) and net assets of \$611,141 (2025: \$2,954,549).

The consolidated entity’s ability to continue as a going concern is dependent on raising further capital to fund the development of its assets. These factors indicate material uncertainty which may cast significant doubt as to whether the consolidated entity will continue as a going concern and therefore whether it will realise its assets and extinguish its liabilities in the normal course of business and at the amounts stated in the financial report.





The Directors believe that there are reasonable grounds to believe that the Company and consolidated entity will continue as a going concern, after consideration of the following factors:

- The Company has the ability to issue additional shares (or other securities) under the *Corporations Act 2001* to raise further working capital and has been successful in doing this previously, as evidenced by the successful shares issued in the recent financial years;
- The Company may be able to access funding for its activities at the project level via investments or grants or a combination of both; and
- The consolidated entity has the ability to scale down its operations in order to curtail expenditure, in the event capital raisings are delayed or insufficient cash is available to meet projected expenditure.

In addition to this:

- In July 2026, Neurotech entered into a secured loan agreement and specific security agreement with Rockford RDF Pty Ltd as trustee for the Rockford RDF Unit Trust for a secured loan of \$3,150,000; and
- In August 2026, Neurotech announced the receipt of binding commitments from investors totalling approximately \$4,500,000 (before costs) through the placement of new fully paid ordinary shares in two tranches at an issue price of \$0.014 per share.

Accordingly, the Directors believe that the consolidated entity will be able to continue as a going concern and that it is appropriate to adopt the going concern basis in the preparation of the financial report.

The consolidated entity's ability to continue as a going concern is mainly dependent on its ability to obtain additional working capital through the issue of equity as and when required.

Should the Group not be able to continue as a going concern, it may be required to realise its assets and discharge its liabilities other than in the ordinary course of business, and at amounts that differ from those stated in the financial statements and that the financial report does not include any adjustments relating to the recoverability and classification of recorded asset amounts or liabilities that might be necessary should the Group not continue as a going concern.

(d) Impact of the Adoption of New Accounting Standards

The Group has adopted all new and amended Accounting Standards and Interpretations issued by the Australian Accounting Standards Board (AASB) that are mandatory for the year ended 30 June 2026. The adoption of these standards did not have a material impact on the Group's financial statements.

Accounting Standards Issued But Not Yet Effective

AASB 18 Presentation and Disclosure in Financial Statements was issued by the AASB in June 2024 and is effective for annual reporting periods beginning on or after 1 January 2027, with earlier application permitted. AASB 18 will replace AASB 101 Presentation of Financial Statements, although many of the existing requirements in AASB 101 will be retained.

AASB 18 introduces new requirements for the presentation and disclosure of information in financial statements, including defined categories and subtotals in the statement of profit or loss, disclosures about management-defined performance measures and enhanced requirements for the aggregation and disaggregation of information.

The Group has not early adopted AASB 18 and is currently assessing the impact of the new Standard on its financial statements. As AASB 18 primarily affects presentation and disclosure, it is not expected to have a material impact on the recognition or measurement of amounts reported in the Group's financial statements.

Significant Accounting Judgments, Estimates and Assumptions

The preparation of the Financial Statements requires Management to make judgments, estimates and assumptions that affect the reported amounts in the Financial Statements. Management continually evaluates its judgments and estimates in relation to assets, liabilities, contingent liabilities, revenue and expenses. Management bases its judgments and estimates on historical experience and various other factors it believes to be reasonable under the circumstances, the result of which forms the basis of the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates. Revisions to accounting estimates are recognised in the period in which the estimate is revised and in any future periods affected.

Information about significant areas of estimation uncertainty and critical judgments in applying accounting policies that have the most significant effect on the amount recognised in the Financial Statements are outlined below:

(i) Share-Based Payments

The Group measures the cost of equity settled transactions with employees by reference to the fair value of equity instruments at the date at which they are granted. The fair value is determined using either a Black-Scholes option pricing model or Up and In Trinomial model depending upon the terms and conditions of the respective share-based payments. Inputs used in valuing share-based payments, including options, are estimates.

(ii) Treatment of Costs Incurred for Research and Development

The Group's consideration of whether its internal projects to develop medical devices are in a research phase or development phase involves significant judgement.

The Group considers a project to be in a development phase when the following can be demonstrated:

- the technical feasibility of completing the intangible asset so that it will be available for use or sale;
- there is intention to complete the project;
- the existence of a market to be able to sell output resulting from the completion of the project;
- how the intangible asset will generate probable future economic benefits;
- there are adequate technical, financial and other resources available to complete the development and to use or sell the intangible asset; and
- expenditure attributable to the project can be reliably measured.

When the above criteria are met, the Group will recognise an intangible asset in relation to the project, otherwise costs incurred to date on the project are expensed as incurred.

(e) Foreign Currency Translation

Functional and Presentation Currency

Items included in the Financial Statements of each of the Group entities are measured using the currency of the primary economic environment in which the Entity operates ('the functional currency'). The Consolidated Financial Statements are presented in Australian dollars (A\$), which is Neurotech International Limited's functional and presentation currency. The functional currency of the subsidiaries of Neurotech International Limited incorporated in Malta is the Euro (EUR).

Translation of Foreign Operations

The Statement of Profit or Loss and Other Comprehensive Income is translated at the average exchange rates for the year.

The exchange differences arising on the translation are taken directly to a separate component of equity. On disposal of the foreign entity, the deferred cumulative amount recognised in equity relating to that foreign operation will be recognised in the Statement of Profit or Loss and Other Comprehensive Income.

(f) Other Income

Research and Development Grants

Government grants relating to research and development activities are recognised when received.

Government Grants

Grants from the government are recognised at their fair value where there is a reasonable assurance that the grant will be received, and the Group will comply with all attached conditions. Government grants relating to the purchase of property, plant and equipment are included in non-current liabilities as deferred income and are credited to profit or loss on a straight-line basis over the expected lives of the related assets.

Government grants relating to costs are deferred and recognised in the profit or loss over the period necessary to match them with the costs that they are intended to compensate.

(g) Trade and Other Receivables

Other receivables are recognised at amortised cost, less any provision for impairment.

(h) Share-Based Payments

Share-based payments, which have been granted to employees, comprise of shares, share rights and share options.

Share Options

The fair value of options granted to employees (including Key Management Personnel) is recognised as an employee benefit expense with a corresponding increase in equity (share-based payments reserve). The fair value is measured at grant date and recognised over the period during which the employees become unconditionally entitled to the options. The fair value at grant date is determined using a Black-Scholes option pricing model that takes into account the exercise price, the term of the option, the vesting and performance criteria, the impact of dilution, the non-tradable nature of the option, the share price at grant date and expected price volatility of the underlying share, the expected dividend yield and the risk-free interest rate for the term of the option.

The fair value of the options granted excludes the impact of any non-market vesting conditions (for example, profitability and sales growth targets). Non-market vesting conditions are included in assumptions about the number of options that are expected to become exercisable. At each reporting date, the Entity revises its estimate of the number of options that are expected to become exercisable. The fair value of the options granted has been determined using the Black-Scholes and Trinomial option pricing models, as appropriate. The fair value measurement incorporates all market-based vesting conditions.

This estimate also requires determination of the most appropriate inputs to the valuation model including the expected life of the share option, volatility and dividend yield and making assumptions about them.

2. Segment Information

The Directors have considered the requirements of AASB 8 – Operating segments. Operating segments are identified, and segment information disclosed on the basis of internal reports that are regularly provided to, or reviewed by, the Group’s chief operating decision maker, which is the Board of Directors. In this regard, such information is provided using similar measures to those used in preparing the consolidated statement of profit or loss and other comprehensive income, consolidated statement of financial position and consolidated statement of cash flows.

One segment is identified, being Clinical Research to assess the neuro-protective, anti-inflammatory and neuro-modulatory activities of NTI164.

3. Other Income

	Consolidated	
	30 June 2026 (\$)	30 June 2025 (\$)
Research and development grants received	4,734,328	2,444,143
Interest income	44,640	137,089
Gain on settlement of trade payables	28,266	-
	4,807,234	2,581,232

4. Share-Based Payments Expense

The primary purpose of share-based payments is to remunerate Directors, other Key Management Personnel and Service providers for the services rendered to the Group.

Share, Options and Performance Rights

	Consolidated	
	30 June 2026 (\$)	30 June 2025 (\$)
Options Issued to Management		
Options issued to Anthony Filippis (CEO)	-	63,764
Expense recognised for the period related to previously issued options to CEO	128,883	14,590
Share and Performance Rights Issued to Service Provider		
Expense recognised for the period related to Class A, B, C, D, and E Performance right previously issued to Fenix	483,333	1,501,690
Total Share-Based Payments Expense	612,216	1,580,044



Options Issued to CEO

On 1 February 2025, Anthony Filippis was appointed as Managing Director and CEO. The Company has issued the following options to Dr Filippis. The options were valued using the Up and In Trinomial model with the following inputs:

	NTIOPT28		NTIOPT29	
	Tranche 1	Tranche 2	Tranche 3	Tranche 4
Number of options	5,000,000	5,000,000	5,000,000	5,000,000
Issue date share price	\$0.05	\$0.05	\$0.05	\$0.05
Exercise price	\$0.16	\$0.16	\$0.18	\$0.18
Expected volatility	68%	68%	68%	68%
Option life	5 years	5 years	5 years	5 years
Expiry	24/02/2030	24/02/2030	24/02/2030	24/02/2030
Interest rate	4.183%	4.183%	4.183%	4.183%
Valuation per Option	\$0.013	\$0.017	\$0.007	\$0.006
Valuation per tranche	\$66,911	\$85,179	\$35,000	\$30,000
Expensed in the period	\$39,597	\$56,786	\$17,500	\$15,000

The above options hold the following vesting conditions:

- 5,000,000 Tranche 1 NTIOPT28 options vested on the first anniversary of the commencement date of Dr Anthony Filippis' as Managing Director and CEO, which happened on 1 February 2025 ('Commencement Date').
- 5,000,000 Tranche 2 NTIOPT28 options will vest upon 18-month period of continuous service in the position from the Commencement Date and the Company filing a market registration application (which is approved by the Board) for NTI164 with the appropriate health regulator in any one of the following markets: Australia, United States of America, European Union, United Kingdom or the Republic of Korea.
- 5,000,000 Tranche 3 NTIOPT29 options will vest upon 24-month period of continuous service in the Position, commencing upon the Commencement Date and Neurotech enters into and completes a legally binding licensing transaction and the Company achieving, after the Commencement Date, an Undiluted Market Capitalisation of at least \$200 million for at least 10 consecutive trading days.
- 5,000,000 Tranche 4 NTIOPT29 options will vest upon 24-month period of continuous service and the Company announcing to the ASX the receipt by the Company of proceeds from the Company's first commercial sale of NTI164 in any market following regulatory approval by the appropriate health regulator (but not including the sale of NTI164 through any special access scheme or authorised prescriber pathway in Australia or in any other market) and the Company achieving, after the Commencement Date, an Undiluted Market Capitalisation of at least \$300 million for at least 10 consecutive trading days.

Detailed remuneration disclosures for Directors and Executives for the year to 30 June 2026 are provided in the Remuneration Report on pages 20 to 25.

Shares and Performance Right Issue to Fenix Innovation Group

On 31 May 2024, the Company had signed an agreement with Fenix Innovation Group to work exclusively with Neurotech in the development of the Company's broad spectrum cannabinoid drug therapy NTI164 for neurological disorders. Subject to shareholder approval, the Company had agreed to issue Fenix (or its nominees) 10 million shares and 50 million performance rights, with vesting conditions based upon the achievement of certain milestones and retention conditions. Shareholder approval was obtained to issue these securities on 10 September 2024 and these securities were issued on 17 September 2024.

The expense of these Performance Rights was calculated by reference to the following inputs:

Input	Class A	Class B	Class C	Class D*	Class E*	Total
Number of performance rights	7,500,000	7,500,000	5,000,000	10,000,000	20,000,000	50,000,000
Share price on agreement date	\$0.07	\$0.07	\$0.07	\$0.07	\$0.07	
Probability of vesting	100%	100%	100%	100%	100%	
Fair value	\$525,000	\$525,000	\$350,000	\$400,000	\$700,000	
Agreement date	31/05/2024	31/05/2024	31/05/2024	31/05/2024	31/05/2024	
Expiry date	31/05/2027	31/05/2027	31/05/2027	31/05/2027	31/05/2027	
Expensed in the financial year ended 30 June 2026	-	-	\$116,667	\$133,333	\$233,333	\$483,333

* Class D and E Rights were valued using the Up and In Trinomial Model. The details of the significant assumptions used are in the table below.

Rights	Class D	Class E
Risk-free rate	4.433%	4.433%
Underlying security spot price	\$0.07	\$0.07
Life of the Rights	3 years	3 years
Volatility	75%	75%
Valuation per Right	\$0.040	\$0.035

The vesting conditions for each class of Performance Rights is as follows:

(i) Class A Performance Rights

Vesting condition: The Company's broad spectrum cannabinoid therapy 'NTI164' (NTI164) receiving an 'Orphan Drug Designation' in the United States of America (US) for any paediatric neurological condition.

Retention conditions: The Collaboration Agreement not having been terminated before the Expiry Date.

Vesting status: The Class A Performance Rights vested on 2 December 2024.

(ii) Class B Performance Rights

Vesting condition: NTI164 receiving an 'Orphan Drug Designation' in the European Union (EU) for any paediatric neurological condition.

Retention conditions: The Collaboration Agreement not having been terminated before the Expiry Date.

Vesting status: The Class B Performance Rights vested on 2 April 2025.

(iii) Class C Performance Rights

Vesting condition: The Company receiving either an 'Investigational New Drug Application' from the Food and Drug Administration of the US or a 'Competent Authority' clearance from the EU for a human clinical trial in any paediatric neurological indication in respect of NTI164.

Retention conditions: The Collaboration Agreement not having been terminated before the Expiry Date.

(iv) Class D Performance Rights

Vesting condition:

- (a) The Company executing a Licence Agreement with a third party for any of the US, EU, Japanese, Canadian or Australian markets in respect of the registration and subsequent sales of NTI164; and
- (b) the volume weighted average price (VWAP) of the Shares remaining at or above \$0.25 per Share for a period of 5 consecutive trading days on which trades in the Shares occur on ASX.

Retention conditions: The Collaboration Agreement not having been terminated before the Expiry Date.

(v) Class E Performance Rights

Vesting condition:

- (a) NTI164 receiving approval (provisional or otherwise) from the Therapeutic Goods Administration of the Federal Government of Australia allowing the Company to market and sell NTI164 in Australia for the treatment of any paediatric neurological disorder; and
- (b) the volume weighted average price (VWAP) of the Shares remaining at or above \$0.30 per Share for a period of 5 consecutive trading days on which trades in the Shares occur on ASX.

Retention conditions: The Collaboration Agreement not having been terminated before the Expiry Date.

5. Research Expenses

Research and Development is a key focal area for the Group and the associated revenue and expenditure is broken down as follows:

	Consolidated	
	30 June 2026 (\$)	30 June 2025 (\$)
Research and development grant income	4,734,328	2,444,143
Research and Development Expenses		
Product development and formulation	320,724	395,007
Clinical program	8,432,995	9,282,705
Patent and IP expenses	171,658	264,176
Other	121,938	-
Total Research and Development Expense	9,047,315	9,941,888

6. Income Tax

The current taxation charge comprises taxation at 30.00% on the profit generated by one of the Group's entities as adjusted for tax purposes.

A deferred taxation asset arising on temporary differences and unused tax losses has not been recognised in these financial statements.

	Consolidated	
	30 June 2026 (\$)	30 June 2025 (\$)
The numerical reconciliation between tax expense and the accounting loss before income tax multiplied by the Group's applicable income tax rate is as follows:		
Accounting (loss) before income tax	(6,538,516)	(10,598,859)
Income tax benefit calculated at the Group's statutory income tax rate of 30.00% (2025: 30.00%)	(1,961,555)	(3,179,658)
Tax effect on non-assessable income	(1,420,298)	(733,243)
Tax effect of non-deductible expenses	201,460	484,931
Tax losses not brought to account	3,180,393	3,427,969
Income tax benefit	-	-

Historical tax losses not brought to account are estimated at \$21,942,022 (2025: \$11,340,713).

The benefit for tax losses will only be obtained if:

- (a) the Group derives future assessable income of a nature and an amount sufficient to enable the benefit from the deductions for the losses to be realised;
- (b) the Group continues to comply with the conditions for deductibility imposed by Law; and
- (c) no changes in tax legislation adversely affect the ability of the Group to realise these benefits.



7. Financial Risk Management

(i) Overview

The financial risks arising from the Group's operations comprise market, liquidity and credit risk. These risks arise in the normal course of business, and the Group manages its exposure to them in accordance with the Group's portfolio risk management strategy.

The objective of the strategy is to support the delivery of the Group's financial targets while protecting its future financial security and flexibility by taking advantage of the natural diversification provided by the scale, diversity and flexibility of the Group's operations and activities.

This note presents information about the Group's exposure to each of the above risks, their objectives, policies and processes for measuring risk and the management of capital.

The Group's Risk Management Framework is supported by the Board. The whole Board is responsible for approving and reviewing the Group's Risk Management Strategy and Policy. Management is responsible for monitoring appropriate processes for identifying, monitoring and managing significant business risks faced by the Group and considering the effectiveness of its internal control system.

The Board has established an overall Risk Management Policy which sets out the Group's system of risk oversight, management of material business risks and internal control.

The Group holds the following financial instruments:

	Consolidated	
	30 June 2026 (\$)	30 June 2025 (\$)
Financial Assets		
Cash and cash equivalents	2,386,402	3,030,955
	2,386,402	3,030,955
Financial Liabilities		
Trade and other payables	2,063,471	220,613
	2,063,471	220,613

(ii) Financial Risk Management Objectives

The overall financial Risk Management Strategy focuses on the unpredictability of the finance markets and seeks to minimise the potential adverse effects on financial performance and protect future financial security.

(iii) Credit Risk

Credit Risk is the risk of the financial loss to the Group if a counterparty to a financial instrument fails to meet its contractual obligations and the risk arises principally from the Group's cash and cash equivalents, deposits with banks and financial institutions, and receivables.

Cash at bank is placed with reliable financial institutions. For banks and financial institutions, the Group banks only with financial institutions with high-quality standing or rating.

The carrying amount of the Group's financial assets represents the maximum credit exposure. The Group's maximum exposure to credit risk at the reporting date was:

	Consolidated	
	30 June 2026 (\$)	30 June 2025 (\$)
Cash at Bank and Commercial Bills		
Cash at bank – National Australia Bank	2,369,692	3,027,638
Cash at bank – Bank of Valletta Plc.**	16,710	3,317
	2,386,402	3,030,955

** Bank of Valletta is currently rated 'BBB-' by an international rating agency.

(iv) Liquidity Risk

Liquidity Risk arises from the financial liabilities of the Group and the Group's subsequent ability to meet their obligations to repay their financial liabilities as and when they fall due.

Ultimate responsibility for Liquidity Risk Management rests with the Board of Directors. The Board has determined an appropriate Liquidity Risk Management Framework for the management of the Group's short, medium and long-term funding and liquidity management requirements. The Group manages liquidity risk by maintaining adequate reserves and continuously monitoring budgeted and actual cash flows and matching the maturity profiles of financial assets, expenditure commitments and liabilities.

The amounts disclosed in the table are the contractual undiscounted cash flows. Balances due within 12 months equal their carrying amounts as the impact of the discounting is not significant.

Contractual Maturities of Financial Liabilities	Less Than 6 months (\$)	6 – 12 Months (\$)	More Than 12 Months (\$)	Total (\$)	Carrying Amount (\$)
Group - at 30 June 2026					
Trade payables	2,063,471	-	-	2,063,471	2,063,471
Total	2,063,471	-	-	2,063,471	2,063,471
Group - at 30 June 2025					
Trade payables	220,613	-	-	220,613	220,613
Total	220,613	-	-	220,613	220,613



(v) Market Risk

Market Risk is the risk that changes in market prices, such as foreign exchange rates may affect the Group's income or the value of its holdings of financial instruments. The objective of Market Risk Management is to manage and control market risk exposures within acceptable parameters, while optimising return.

Foreign Exchange Risk

The Group is exposed to currency risk on financial assets or liabilities that are denominated in a currency other than the respective functional currencies of the Group: the Australian Dollar (AUD) for Parent Entity and Euro (EUR) for the subsidiaries of Consolidated Entity.

The Parent Entity which has a functional currency of Australian Dollars has no exposure to foreign exchange risk as there are no financial assets or liabilities denominated in a foreign currency (30 June 2025: nil). The subsidiaries of the Parent Entity, which have a functional currency of EUR, have exposure to foreign exchange risk; however, the exposure is considered immaterial as at 30 June 2026 (30 June 2025: immaterial).

Interest Rate Risk

The Group's exposure to interest rates primarily relates to the Group's cash and cash equivalents. As the Group has no significant interest-bearing assets, its income and operating cash flows are substantially independent of changes in market interest rates. The Group had no interest-bearing liabilities.

Profile

At the reporting date, the interest rate profile of the Group's and the Entity's interest-bearing financial instruments are:

Variable Rate Instruments

	Consolidated	
	30 June 2026 (\$)	30 June 2025 (\$)
Financial assets	2,386,402	3,030,955
Financial liabilities	-	-
	2,386,402	3,030,955

As at 30 June 2026 the Group had no interest-bearing borrowings or other liabilities.

The Group's exposure to interest rate risk and effective weighted average interest rate by maturing periods is set out in tables below. All cash balances and borrowings are subject to a floating interest rate. The Group does not earn interest on cash held in the EUR currency, and the below stated weighted average interest rate reflects this.

30 June 2026

	Weighted Average Effective Interest Rate	Cash Available For Use	Total
Cash and cash equivalents	4.8%	2,386,402	2,386,402

30 June 2025

	Weighted Average Effective Interest Rate	Cash Available For Use	Total
Cash and cash equivalents	4.52%	3,030,955	3,030,955

Up to the end of the reporting period, the Group did not have any hedging policy with respect to interest rate risk as exposure to such risk was not deemed to be significant by the directors since these assets are of a short-term nature. Management considers the potential impact on profit or loss of a defined interest rate shift that is reasonably probable at the end of the reporting period to be immaterial.

Cash Flow Sensitivity Analysis for Variable Rate Instruments

The Board's assessment of a reasonably possible change in interest rates relating to the Company's Cash and Cash equivalents and borrowings is disclosed in the table below:

	Number of Basis Points
Cash and cash equivalents	-75

Management considers the potential impact on profit or loss of a reasonably possible change in interest rates at the end of the reporting period to be immaterial based on the prevailing interest rates.

8. Capital Management

When managing capital, the Board's objective is to maintain optimal returns to Shareholders and benefits for other Stakeholders. The Board also aims to maintain a capital structure that ensures the lowest cost of capital available to the Group. The Group has no formal financing and gearing policy or criteria during the year having regard to the early status of its development and low level of activity. This position has not changed from the previous year.

9. Cash and Cash Equivalents

Cash and cash equivalents included in the Consolidated Statement of Cash Flows comprise the following Consolidated Statement of Financial Position amounts:

	Consolidated	
	30 June 2026 (\$)	30 June 2025 (\$)
Cash at bank and on hand	871,402	3,015,955
Term deposit	1,515,000	15,000
	2,386,402	3,030,955

The term deposit amount of \$15,000 is used as security for credit cards. No amount of the Group's Cash at bank and on hand is restricted (30 June 2025: Nil). Refer to Note 7 Financial Risk Management for risk exposure analysis for Cash and cash equivalents.



10. Trade and Other Receivables

	Consolidated	
	30 June 2026 (\$)	30 June 2025 (\$)
GST/VAT/Sales Tax Receivable	342,339	88,704
	342,339	88,704

11. Payables

	Consolidated	
	30 June 2026 (\$)	30 June 2025 (\$)
Trade payables	2,065,101	220,613
Accrued expenses	57,134	58,667
	2,122,235	279,280

12. Provisions

	Consolidated	
	30 June 2026 (\$)	30 June 2025 (\$)
Provisions for annual leave	14,016	6,462
	14,016	6,462

13. Contributed Equity

	Consolidated			
	2026 (Shares)	2025 (Shares)	2026 (\$)	2025 (\$)
Ordinary shares	1,317,741,687	1,049,621,921	52,494,008	48,914,346
Total Share Capital	1,317,741,687	1,049,621,921	52,494,008	48,914,346

Movements of Share Capital During the Year

Date	Details	No of Shares	Issue Price (\$)	\$
Opening Balance at 1 July 2025		1,049,621,921		48,914,346
24.12.2025	Placement	246,691,196	0.014	3,453,676
30.03.2026	Placement	21,428,570	0.014	300,000
	Capital raising costs			(174,014)
Closing Balance at 30 June 2026		1,317,741,687		52,494,008

The holder of Ordinary Shares is entitled to participate in dividends and the proceeds on winding up of the Group in proportion to the number of and amounts paid on the shares held. On a show of hands every holder of ordinary shares present at a meeting in person or by proxy, is entitled to one vote, and upon a poll each share is entitled to one vote. Ordinary Shares have no par value and the Group does not have a limited amount of authorised capital.

Movements of Share Capital During the Previous Year

Date	Details	No of Shares	Issue Price (\$)	\$
Opening Balance at 1 July 2024		1,017,388,587		46,734,820
27.08.2024	Exercise of NTIOPT26S	200,000	0.06	12,000
13.09.2024	Exercise of NTIOPT26S	7,033,334	0.06	422,000
17.09.2024	Issue of 10,000,000 shares to Fenix	10,000,000	0.07	700,000
02.12.2024	Conversion of 7,500,000 Class A NTIPERR2 Performance Rights - Fenix	7,500,000	0.07	525,000
01.06.2025	Conversion of 7,500,000 Class B NTIPERR2 Performance Rights - Fenix	7,500,000	0.07	525,000
	Capital raising costs			(4,474)
Closing Balance at 30 June 2025		1,049,621,921		48,914,346

14. Reserves

	Consolidated		
	Share-Based Payments Reserve (\$)	Foreign Currency Translation Reserve (\$)	Total Reserves (\$)
Balance as at 30 June 2024	7,026,501	(305,339)	6,721,162
Foreign exchange movement	-	(354,849)	(354,849)
Converted to shares	(1,750,000)	-	(1,750,000)
Share-based payments	1,580,044	-	1,580,044
Balance as at 30 June 2025	6,856,545	(660,188)	6,196,357
Foreign exchange movement	-	3,230	3,230
Share-based payments	612,216	-	612,216
Balance as at 30 June 2026	7,468,761	(656,958)	6,811,803

(a) Share-Based Payments Reserve

The share-based payments reserve represents the value of options and share rights issued to key management personnel, vendors and for services in relation to capital raisings. The share-based payments reserve is used to record the value of the share-based payments provided to employees, consultants and for options issued pursuant to any acquisition or in exchange for services.

(b) Foreign Currency Reserve

The foreign currency reserve records foreign currency differences arising from the translation of financial information of the Group's Maltese subsidiaries which have a functional currency of the Euro.

15. Accumulated Profit/(Loss)

	Consolidated	
	30 June 2026 (\$)	30 June 2025 (\$)
Accumulated (loss) at the beginning of the year	(52,156,154)	(41,557,295)
Loss attributable to shareholders	(6,538,516)	(10,598,859)
Accumulated (loss) at the end of the year	(58,694,670)	(52,156,154)

16. Cash Flow Information

	Consolidated	
	30 June 2026 (\$)	30 June 2025 (\$)
Reconciliation of cash flow from operating activities with the loss from continuing operations after income tax:		
Non-Cash Flows in Profit from Ordinary Activities		
Net (loss) after income tax	(6,538,516)	(10,598,859)
Share-based payments	612,216	1,580,044
Forex gain/(loss)	3,230	(354,849)
Depreciation	-	289
Changes in Assets and Liabilities		
(Increase)/decrease in trade and other receivables	(253,634)	229,349
Decrease in prepayments	101,980	148,932
Increase/(decrease) in trade and other payables	1,850,509	(28,957)
Cash Flow Used in Operating Activities	(4,224,215)	(9,024,051)

17. Interests In Other Entities

Name of Entity	Place of Business/ Country of Incorporation	Ownership Interest Held by the Group		Principal Activities
		2026	2025	
AAT Research Ltd	Malta	100%	100%	Parent Group of AAT Medical Ltd
AAT Medical Ltd	Malta	100%	100%	Executing medical research projects and developing novel technological devices that are marketable



18. Matters Subsequent to the End of the Financial Year

US FDA Clears IND for NTI164

In July 2026, the Company announced that the US Food and Drug Administration (FDA) has cleared the Company's Investigational New Drug (IND) submission for NTI164.

The IND clearance authorises Neurotech to commence its proposed clinical development program for NTI164 in the United States and represents a major regulatory milestone for the Company. The IND submission included the Company's chemistry, manufacturing and controls (CMC), non-clinical and clinical information supporting the proposed clinical and development program.

Should the Company elect to commence clinical development in the United States, the study to be conducted under the FDA-cleared IND will be a comprehensive population pharmacokinetic (PopPK) program. The program has been strategically designed to complement the Company's Australian Phase III "Beyond Harmony" trial, which is intended to generate pivotal efficacy and safety data for NTI164 in paediatric patients with ASD. The Phase III results are expected to form an important component of the global clinical evidence package supporting future regulatory submissions, while the US PopPK study would generate vital pharmacokinetic data to support dose characterisation and product registration initiatives.

Notices of Allowance for Two US Patent Applications

In July 2026, the Company advised that the United States Patent and Trademark Office (USPTO) sent Notices of Allowance for US patent applications No. 18/698,605 and No. 19/335,945 to Neurotech. These applications relate to key aspects of the Company's NTI164 product and are both titled "Compositions and Methods for Treating Neurological Disorders".

The allowed claims of US Patent Application No. 18/698,605 cover methods of reducing neuroinflammation using NTI164 and the allowed claims of US Patent Application No. 19/335,945 are specifically directed to methods of treating autism spectrum disorder.

Once granted, these patents are expected to further strengthen Neurotech's intellectual property portfolio for NTI164, which is currently in Phase III clinical development for the treatment of ASD in paediatric patients. The patents will not be enforceable until formally granted. The Notices of Allowance confirm that the USPTO has determined the applications meet the requirements for patentability and issuance of two US patents is expected within the coming months, subject to completion of standard administrative processes. Subject to the payment of applicable maintenance fees, these patents are expected to provide intellectual property protection for NTI164 through to 2042.

\$3,150,000 R&D Tax Incentive Loan

In July 2026, Neurotech entered into a secured loan agreement and specific security agreement with Rockford RDF Pty Ltd as trustee for the Rockford RDF Unit Trust for a secured loan of \$3,150,000.

The loan provides Neurotech with non-dilutive funding secured against the Company's anticipated refundable research and development tax incentive offsets for FY2026 and FY2027. Further details on this loan are set out in the Company's ASX announcement dated 15 July 2026.

Receipt of Binding Commitments for ~\$4,500,000 Placement

In August 2026, Neurotech announced the receipt of binding commitments from investors totalling approximately \$4,500,000 (before costs) through the placement of new fully paid ordinary shares in two tranches ('Placement Shares') at an issue price of \$0.014 per share ('Placement'). The Placement was supported by existing and new institutional and sophisticated investors and was managed by Taylor Collison Limited and Canary Capital Pty Ltd as Joint Lead Managers.

Funds raised will predominantly be used to fund the Company's Phase III double-blind, placebo-controlled clinical trial of NTI164 in children with Autism Spectrum Disorder (ASD), as well as regulatory activities, general working capital and costs associated with the Placement. Subject to completion of the Placement, based on Neurotech's current clinical development plan and budget, and together with its existing cash, the Company expects that the net proceeds of the Placement will fund Neurotech through to topline data readout from the Phase III clinical trial which is anticipated to represent a significant milestone in the Company's development pathway for NTI164.

Appointment of Executive Chairman

In August 2026, the Company announced the appointment of Mr Mark Davies as Executive Chairman of the Company, effective 17 August 2026. Mr Davies transitioned from his previous role as Non-Executive Chairman.

As Executive Chairman, Mr Davies will assume a more active role in the strategic and operational leadership of Neurotech. His responsibilities will include corporate strategy, capital markets and funding initiatives, partnering and licensing activities, investor engagement, governance, and strategic oversight of the Company's clinical and regulatory programs.

The appointment reflects the Company's progression into its next stage of development, with an increased focus on the Phase III program, funding strategy and potential partnering and licensing opportunities.





19. Remuneration of Auditor

During the financial year the following fees were paid or payable for services provided by BDO, the auditor of the Company.

	Consolidated	
	30 June 2026 (\$)	30 June 2025 (\$)
Audit and Other Assurance Services		
Audit services - BDO	67,580	63,954
Total Remuneration for Auditing or Reviewing the Financial Report	67,580	63,954

20. Commitments

The Company has no commitments not recognised as liabilities as at 30 June 2026 (2025: \$nil).

21. Loss Per Share

	Consolidated	
	30 June 2026 (\$)	30 June 2025 (\$)
Basic loss per share (cents per share)	(0.55)	(1.02)
Diluted loss per share (cents per share)	(0.55)	(1.02)
(Loss) Used in the Calculation of Earnings (Loss) Per Share	(6,538,516)	(10,598,859)
Weighted average number of ordinary shares	1,182,085,957	1,035,891,510

Effect of dilutive securities: Share options are not considered dilutive as the conversion of options to ordinary shares will result in a decrease in the net loss per share.

22. Contingent Liabilities

The Board is not aware of any circumstances or information, which leads them to believe there are any material contingent liabilities outstanding as at 30 June 2026.

23. Fair Values of Financial Assets and Liabilities

At 30 June 2026 and 30 June 2025, the carrying amounts of financial assets and financial liabilities classified with current assets and current liabilities respectively approximated their fair values due to the short-term maturities of these assets and liabilities. The fair values of non-current financial assets and non-current financial liabilities are not materially different from their carrying amounts.

24. Related Party Disclosures

Parent Entity

The legal Parent Entity of the Group is Neurotech International Limited (NTI). NTI owns 100% of the issued ordinary shares of AAT Research Limited (directly), AAT Medical Limited (indirectly) which is the subsidiary of AAT Research Limited. All subsidiaries are incorporated in Malta.

Key Management Personnel

	Consolidated	
	30 June 2026 (\$)	30 June 2025 (\$)
Short-term employee benefits	684,416	677,166
Share-based payment	128,883	78,355
	813,299	755,521

Detailed remuneration disclosures for Directors and Executives for the year to 30 June 2026 are provided in the Remuneration Report on pages 20 to 25.

Transactions with other related parties

No related party transactions occurred during the financial year.

25. Parent Entity Information

The following information related to the Parent Entity, Neurotech International Limited, as at 30 June 2026.

The information presented here has been prepared using accounting policies as presented in Note 1.

	30 June 2026 (\$)	30 June 2025 (\$)
Current assets	2,391,478	3,148,934
Total Assets	2,391,478	3,148,934
Current liabilities	2,119,949	228,435
Total Liabilities	2,119,949	228,435
Net Assets	271,529	2,920,499
Loss for the year	(6,544,154)	(10,922,758)
Other comprehensive profit/(loss) for the year	-	-
Total Comprehensive Loss for the Year	(6,544,154)	(10,922,758)

There are no other separate commitments and contingencies for the parent entity as at 30 June 2026.

Consolidated Entity Disclosure Statement

Name of Entity*	Type of Entity	Trustee, Partner or Participant in Joint Venture**	% of Share Capital Held	Country of Incorporation	Australian Resident	Foreign Jurisdiction(s) in Which the Entity is a Resident for Tax Purposes (According to the Law of the Foreign Jurisdictions)***
Neurotech International	Body Corporate	-	100%	Australia	Yes	N/A
AAT Medical Ltd	Body Corporate	-	100%	Malta	No	Malta
AAT Research Ltd	Body Corporate	-	100%	Malta	No	Malta

* Entities listed here are those that are part of the consolidated entity at the end of the financial year. Entities disposed of during the year, or where the entity has lost control by the reporting date, are not included. This means that entities listed could be different to the 'Interests in subsidiaries' note contained in the notes to the financial statements.

** This means whether, at that time, the entity was a trustee of a trust within the consolidated entity, a partner in a partnership within the consolidated entity, or a participant in a joint venture within the consolidated entity.

*** It is possible in rare cases for an entity to be a tax resident of both Australia and another jurisdiction.

Basis of Preparation

The Consolidated Entity Disclosure Statement has been prepared in accordance with the Corporations Act 2001 and includes information for each entity that was part of the consolidated entity as at the end of the financial year in accordance with AASB 10 Consolidated Financial Statements.

Directors' Declaration

In the opinion of the Directors of Neurotech International Limited (Group):

- (a) the Financial Statements, comprising the consolidated statement of profit or loss and other comprehensive income, consolidated statement of financial position, consolidated statement of cash flows, consolidated statement of changes in equity, and Notes set out on pages 31 to 55, are in accordance with the Corporations Act 2001, including:
 - (i) giving a true and fair view of the Group's financial position as at 30 June 2026 and of its performance, for the financial period ended on that date; and
 - (ii) complying with Australian Accounting Standards (including the Australian Accounting Interpretations) and Corporations Regulations 2001; and other mandatory professional reporting requirements.
- (b) the Financial Report also complies with International Financial Reporting Standards as disclosed in Note 1.
- (c) there are reasonable grounds to believe that the Group will be able to pay its debts as and when they become due and payable.
- (d) the consolidated entity disclosure statement on page 56 is true and correct.

The Directors have been given the declarations required by Section 295A of the Corporations Act 2001 by the Financial Officer for the financial period ended 30 June 2026.

Signed in accordance with a resolution of the Directors.



Mark Davies
Executive Chairman
26 August 2026

Independent Auditor's Report



Tel: +61 8 6382 4600
Fax: +61 8 6382 4601
www.bdo.com.au

Level 9, Mia Yellagonga Tower 2
5 Spring Street
Perth, WA 6000
PO Box 700 West Perth WA 6872
Australia

INDEPENDENT AUDITOR'S REPORT

To the members of Neurotech International Limited

Report on the Audit of the Financial Report

Opinion

We have audited the financial report of Neurotech International Limited (the Company) and its subsidiaries (the Group), which comprises the consolidated statement of financial position as at 30 June 2026, the consolidated statement of profit or loss and other comprehensive income, the consolidated statement of changes in equity and the consolidated statement of cash flows for the year then ended, and notes to the financial report, including material accounting policy information, the consolidated entity disclosure statement and the directors' declaration.

In our opinion the accompanying financial report of the Group, is in accordance with the Corporations Act 2001, including:

- (i) Giving a true and fair view of the Group's financial position as at 30 June 2026 and of its financial performance for the year ended on that date; and
- (ii) Complying with Australian Accounting Standards and the Corporations Regulations 2001.

Basis for opinion

We conducted our audit in accordance with Australian Auditing Standards. Our responsibilities under those standards are further described in the Auditor's responsibilities for the audit of the Financial Report section of our report. We are independent of the Group in accordance with the Corporations Act 2001 and the ethical requirements of the Accounting Professional and Ethical Standards Board's APES 110 Code of Ethics for Professional Accountants (including Independence Standards) (the Code) that are relevant to our audit of the financial report in Australia. We have also fulfilled our other ethical responsibilities in accordance with the Code.

We confirm that the independence declaration required by the Corporations Act 2001, which has been given to the directors of the Company, would be in the same terms if given to the directors as at the time of this auditor's report.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Material uncertainty related to going concern

We draw attention to Note 1 (c) in the financial report which describes the events and/or conditions which give rise to the existence of a material uncertainty that may cast significant doubt about the group's ability to continue as a going concern and therefore the group may be unable to realise its assets and discharge its liabilities in the normal course of business. Our opinion is not modified in respect of this matter.

BDO Audit Pty Ltd ABN 33 134 022 870 is a member of a national association of independent entities which are all members of BDO International Ltd, a UK company limited by guarantee, and form part of the international BDO network of independent member firms. Liability limited by a scheme approved under Professional Standards Legislation.



Key audit matters

Key audit matters are those matters that, in our professional judgement, were of most significance in our audit of the financial report of the current period. These matters were addressed in the context of our audit of the financial report as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters. Except for the matter described in the Material Uncertainty Related to Going Concern section, we have determined that there are no other key audit matters to communicate in our report.

Other information

The directors are responsible for the other information. The other information comprises the information in the Group's annual report for the year ended 30 June 2026, but does not include the financial report and the auditor's report thereon.

Our opinion on the financial report does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial report, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial report or our knowledge obtained in the audit or otherwise appears to be materially misstated.

If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Responsibilities of the directors for the Financial Report

The directors of the Company are responsible for the preparation of:

- a) the financial report that gives a true and fair view in accordance with Australian Accounting Standards and the Corporations Act 2001 and
- b) the consolidated entity disclosure statement that is true and correct in accordance with the Corporations Act 2001, and

for such internal control as the directors determine is necessary to enable the preparation of:

- i) the financial report that gives a true and fair view and is free from material misstatement, whether due to fraud or error; and
- ii) the consolidated entity disclosure statement that is true and correct and is free of misstatement, whether due to fraud or error.

In preparing the financial report, the directors are responsible for assessing the ability of the group to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the Group or to cease operations, or has no realistic alternative but to do so.



Auditor's responsibilities for the audit of the Financial Report

Our objectives are to obtain reasonable assurance about whether the financial report as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with the Australian Auditing Standards will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of this financial report.

A further description of our responsibilities for the audit of the financial report is located at the Auditing and Assurance Standards Board website (<http://www.auasb.gov.au/Home.aspx>) at:

https://www.auasb.gov.au/media/bwvjcgre/ar1_2024.pdf

This description forms part of our auditor's report.

Report on the Remuneration Report

Opinion on the Remuneration Report

We have audited the Remuneration Report included in pages 20 to 25 of the directors' report for the year ended 30 June 2026.

In our opinion, the Remuneration Report of Neurotech International Limited, for the year ended 30 June 2026, complies with section 300A of the *Corporations Act 2001*.

Responsibilities

The directors of the Company are responsible for the preparation and presentation of the Remuneration Report in accordance with section 300A of the *Corporations Act 2001*. Our responsibility is to express an opinion on the Remuneration Report, based on our audit conducted in accordance with Australian Auditing Standards.

BDO Audit Pty Ltd

John Christides

Director

Perth, 26 August 2026

Additional ASX Information



Chairman's
Letter

Directors'
Report

Financial
Statements

Additional
Information

The shareholder information set out below was applicable as at 3 August 2026.

1. Quotation

Listed securities in Neurotech International Limited are quoted on the Australian Securities Exchange under ASX code NTI (Fully Paid Ordinary Shares).

2. Voting Rights

The voting rights attached to the Fully Paid Ordinary Shares of the Company are:

- (a) at a meeting of members or classes of members each member entitled to vote may vote in person or by proxy or by attorney; and
- (b) on a show of hands, every person present who is a member has one vote, and on a poll every person present in person or by proxy or attorney has one vote for each ordinary share held.

There are no voting rights attached to any Options or Performance Rights on issue.



3. Distribution of Shareholders

(i) Fully Paid Ordinary Shares

Holdings Range	Holders	Units	%
1 – 1,000	72	10,818	0.00
1,001 – 5,000	102	367,443	0.03
5,001 – 10,000	381	3,127,497	0.24
10,001 – 100,000	1,086	45,636,960	3.45
100,001 and above	732	1,273,598,969	96.28
Total	2,373	1,322,741,687	100.00

On 3 August 2026, there were 1,066 holders of unmarketable parcels of less than 31,250 ordinary shares (based on the closing share price of \$0.016).

(ii) NTIOPT18 - Unlisted Options exercisable at \$0.10 on or before 23 December 2027

Holdings Range	Holders	Units	%
1 – 1,000	-	-	-
1,001 – 5,000	-	-	-
5,001 – 10,000	-	-	-
10,001 – 100,000	-	-	-
100,001 and above	1	10,000,000 ¹	100.00
Total	1	10,000,000	100.00

¹ All the securities in this class are held by Cipa Investments Pty Ltd <Cipa Investments A/C>

(iii) NTIOPT19 - Unlisted Options exercisable at \$0.15 on or before 23 December 2027

Holdings Range	Holders	Units	%
1 – 1,000	-	-	-
1,001 – 5,000	-	-	-
5,001 – 10,000	-	-	-
10,001 – 100,000	-	-	-
100,001 and above	1	10,000,000 ¹	100.00
Total	1	10,000,000	100.00

¹ All the securities in this class are held by Cipa Investments Pty Ltd <Cipa Investments A/C>

(iv) NTIOPT28 - Unlisted Options exercisable at \$0.16 on or before 24 February 2030

Holdings Range	Holders	Units	%
1 – 1,000	-	-	-
1,001 – 5,000	-	-	-
5,001 – 10,000	-	-	-
10,001 – 100,000	-	-	-
100,001 and above	1	10,000,000 ¹	100.00
Total	1	10,000,000	100.00

¹ All the securities in this class are held by Antfilippis Investments Pty Ltd <The Filippis Family Account>

(v) NTIOPT29 - Unlisted Options exercisable at \$0.18 on or before 24 February 2030

Holdings Range	Holders	Units	%
1 – 1,000	-	-	-
1,001 – 5,000	-	-	-
5,001 – 10,000	-	-	-
10,001 – 100,000	-	-	-
100,001 and above	1	10,000,000 ¹	100.00
Total	1	10,000,000	100.00

¹ All the securities in this class are held by Antfilippis Investments Pty Ltd <The Filippis Family Account>

(vi) NTIOPT30 - Unlisted Options exercisable at \$0.02 on or before 13 July 2028

Holdings Range	Holders	Units	%
1 – 1,000	-	-	-
1,001 – 5,000	-	-	-
5,001 – 10,000	-	-	-
10,001 – 100,000	-	-	-
100,001 and above	8	13,000,000 ¹	100.00
Total	8	13,000,000	100.00

¹ Holders that hold more than 20% of these securities are: Insync Equity Services Pty Ltd – 4,550,000 options; CBXSEN Pty Ltd <Sengupta Family A/C> - 4,550,000 options

(vii) NTIOPT31 - Unlisted Options exercisable at \$0.03 on or before 13 July 2029

Holdings Range	Holders	Units	%
1 – 1,000	-	-	-
1,001 – 5,000	-	-	-
5,001 – 10,000	-	-	-
10,001 – 100,000	-	-	-
100,001 and above	8	6,500,000 ¹	100.00
Total	8	6,500,000	100.00

¹ Holders that hold more than 20% of these securities are: Insync Equity Services Pty Ltd – 2,275,000 options; CBXSEN Pty Ltd <Sengupta Family A/C> - 2,275,000 options

(viii) NTIPERR2 – Performance Rights expiring on 17 September 2027

Holdings Range	Holders	Units	%
1 – 1,000	-	-	-
1,001 – 5,000	-	-	-
5,001 – 10,000	-	-	-
10,001 – 100,000	-	-	-
100,001 and above	1	30,000,000 ¹	100.00
Total	1	30,000,000	100.00

¹ All the securities in this class are held by Fenix Innovation Group Pty Ltd



4. Substantial Shareholders

The names of the substantial shareholders as notified to the Company as at 3 August 2026 are:

Name	Holder of	Notice Received
Biotech Capital Management Pty Ltd as investment manager of the Merchant Biotech Fund and related entities	54,987,203 Shares, representing 5.4% as at 13 September 2024	17 September 2024
Dutch Ink Pty Ltd	94,341,233 Shares, representing 9.11% as at 4 October 2024	7 October 2024
Merchant Funds Management Pty Ltd as manager of the Merchant Opportunities Fund & Merchant Group Pty Ltd	53,099,919 Shares, representing 5.1% as at 9 December 2024	12 December 2024

5. Restricted Securities

There are no restricted securities listed on the Company’s register as at 3 August 2026.

6. On Market Buy-Back

There is currently no on market buy-back in place.

7. Twenty Largest Shareholders

The twenty largest shareholders of the Company’s quoted securities as at 3 August 2026 are as follows:

	Holder Name	Holding	%
1	J & J Bandy Nominees Pty Ltd <Bandy P/F A/C>	49,000,000	3.70
2	Jalaver Pty Ltd <Falcon Pension A/C>	48,000,000	3.63
3	The Trust Company (Australia) Limited <MOF A/C>	37,649,358	2.85
4	Dutch Ink (2010) Pty Ltd	37,000,000	2.80
5	Mr Josephus Jeffrey Verheggen	27,758,724	2.10
6	Chincherinchee Nominees Pty Ltd	27,693,572	2.09
7	Fenix Innovation Group Pty Ltd	25,291,269	1.91
8	Dutch Ink (2010) Pty Ltd	24,397,522	1.84
9	Citicorp Nominees Pty Limited	22,948,158	1.73
10	HSBC Custody Nominees (Australia) Limited - A/C 2	21,502,315	1.63
11	Seivad Investments Pty Ltd <Davies Family A/C>	18,935,875	1.43
12	Mrs Melanie Therese Verheggen	18,017,328	1.36
13	MB Investment Capital Pty Ltd	17,084,226	1.29
14	Gofour Sail Pty Ltd	17,073,000	1.29
15	Mr Vedat Isikgel	16,221,427	1.23
16	Mr Caiwen Xu	16,200,000	1.22
17	Britoak Pty Ltd	16,186,351	1.22
18	Myall Resources Pty Ltd <Myall Group Super Fund A/C>	14,000,000	1.06
19	Surf Coast Capital Pty Ltd <Minnie P/F A/C>	13,731,823	1.04
20	Diamond Construct Pty Ltd	12,650,000	0.96
Total		481,340,948	36.39





Neurotech
International

neurotechinternational.com